Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

Basch, Ethan; Hesketh, Paul J.; Kris, Mark G.; Prestrud, Ann Alexis; Temin, Sarah; Lyman, Gary H.

doi:10.1200/jop.2011.000397

Cited by 200 publications

(302 citation statements)

References 6 publications

Supporting

Mentioning

278

Contrasting

Unclassified

Order By: Relevance

“…Although no randomized study has compared the antiemetic potency of available corticosteroids, the most frequently used steroid as an antiemetic is dexamethasone. Dexamethasone is usually used in combination with serotonin (5-hydroxytryptamine 3 ) or neurokinin-1 receptor antagonists for highly or moderately emetogenic chemotherapy or as monotherapy for mildly emetogenic chemotherapy [6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

A Prospective Multicenter Study Evaluating Secondary Adrenal Suppression After Antiemetic Dexamethasone Therapy in Cancer Patients Receiving Chemotherapy: A Korean South West Oncology Group Study

Han

Park

et al. 2015

The Oncologist

View full text Add to dashboard Cite

Background. In a previous pilot study, adrenal suppression was found to be common after antiemetic dexamethasone therapy in cancer patients.The objective of this large prospective multicenter study was to confirm the incidence and factors associated with secondary adrenal suppression related to antiemetic dexamethasone therapy in cancer patients receiving chemotherapy. Methods. Chemotherapy-naïve patients who were scheduled to receive at least three cycles of highly or moderately emetogenic chemotherapy with dexamethasone as an antiemetic were enrolled. Patients with a suppressed adrenal response before chemotherapy or those administered corticosteroids within 6 months of enrollment in the study were excluded. Results. Between October 2010 and August 2014, 481 patients receiving chemotherapy underwent the rapid adrenocorticotropic hormone (ACTH) stimulation test to assess eligibility; 350 of these patients were included in the final analysis. Fifty-six

show abstract

Section: Introductionmentioning

confidence: 99%

A Prospective Multicenter Study Evaluating Secondary Adrenal Suppression After Antiemetic Dexamethasone Therapy in Cancer Patients Receiving Chemotherapy: A Korean South West Oncology Group Study

Han

Park

et al. 2015

The Oncologist

View full text Add to dashboard Cite

show abstract

“…At the MASCC meeting in Rome (June 2009), palonosetron was put forward as the setron of choice for MEC. [27][28][29][30] As stated before, adherence to guidelines is one of the three risk factors for patients receiving HEC or MEC. Unfortunately, it is known that adherence to and implementation of recommendations are below the optimal level.…”

Section: Clinical Guidelinesmentioning

confidence: 99%

“…Table 2 lists the actual antiemetic guidelines. [27][28][29][30] There is a strong degree of concordance between the different guidelines. Triple therapy with a setron, dexamethasone, and an NK-1 receptor antagonist is the regimen of preference for acute emesis due to HEC.…”

Section: Clinical Guidelinesmentioning

confidence: 99%

Corticosteroids, the oldest agent in the prevention of chemotherapy-induced nausea and vomiting: What about the guidelines?

Ryckeghem

2016

Journal of Translational Internal Medicine

View full text Add to dashboard Cite

Chemotherapy-induced nausea and vomiting (CINV) remains one of the most disturbing side effects of cancer treatment. Research in antiemetic therapy has progressed gradually since the early eighties, and the development of antiemetic agents continues. This review focuses on the current management of CINV based on the most recent guidelines, and adherence to the latter is examined more carefully. Setrons (5HT3 receptor antagonists), corticosteroids, and NK-1 receptor antagonists are the cornerstones of antiemetic therapy. Corticosteroids are one of the oldest agents in the prevention of CINV. They are highly effective, increase the effect of other antiemetic agents, and are cost-effective. The latest developed 5HT3 receptor antagonist palonosetron led to an update of the guidelines of CINV. Other types include benzodiazepines, cannabinoids, and olanzapine. Various factors contribute to the overall risk of developing CINV, such as patient characteristics, emetogenic potency of the chemotherapeutic agents, and correct prevention of CINV. Current guidelines determine which is the right preventive regimen for each cancer patient at risk for experiencing CINV. Adherence to these guidelines and implementation in daily practice seem to be below the optimal level. In Belgium, authorities use the guidelines as a base for reimbursement and this has increased the level of implementation.

show abstract

“…The oral neurokinin-1 receptor antagonist aprepitant is an antiemetic drug with a new mechanism of action that not only shows efficacy for acute CINV (within 24 hours of starting chemotherapy) but also for delayed CINV (24 hours or more after starting chemotherapy), which is poorly controlled by current therapies, and the efficacy of aprepitant against the emetic effect of singledose cisplatin has been demonstrated (Roila et al, 2010;Basch et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

“…We employ a daily cisplatin regimen (FP therapy with daily administration of cisplatin at 20mg/m 2 from Day 1 to Day 4 and 5-fluorouracil (5-FU) at 400 mg/m 2 from Day 1 to Day 5) (Brizel et al, 1998) to treat patients with head and neck cancer (HNC), but there have been few studies on the efficacy of aprepitant during daily administration of cisplatin and no specific antiemetic regimen for daily cisplatin therapy has been established (Roila et al, 2010;Basch et al, 2011;Einhorn et al, 2011). When FP therapy is performed at our department, severe nausea tends to occur on or after the last day of cisplatin administration and it has a strong impact on quality of life (Sun et al, 2005).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Aprepitant for Nausea in Patients with Head and Neck Cancer Receiving Daily Cisplatin Therapy

Ishimaru

Takano²,

Katsura³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Although efficacy of aprepitant for suppressing emesis associated with single-dose cisplatin has been demonstrated, there are limited data on the antiemetic effect of this oral neurokinin-1 receptor antagonist during daily administration of cisplatin. Accordingly, we investigated the efficacy and safety of aprepitant in patients with head and neck cancer (HNC) receiving combination therapy with cisplatin and 5-FU (FP therapy). Materials and Methods: Twenty patients with HNC were prospectively studied who received a triple antiemetic regimen comprising granisetron (40μg/kg on Days 1-4), dexamethasone (8 mg on Days 1-4), and aprepitant (125 mg on day 1 and 80mg on days 2-5) with FP therapy (cisplatin 20 mg/m 2 on days 1-4; 5-FU 400 mg/m 2 on days 1-5) (aprepitant group). We also retrospectively studied another 20 HNC patients who received the same regimen except for aprepitant (control group). Results: For efficacy endpoints based on nausea, the aprepitant group showed significantly better results, including a higher rate of complete response (no vomiting and no salvage therapy) for the acute phase (p=0.0342), although there was no marked difference between the two groups with regard to percentage of patients in whom vomiting was suppressed. There were no clinically relevant adverse reactions to aprepitant. Conclusions: This study suggested that a triple antiemetic regimen containing aprepitant is safe and effective for HNC patients receiving daily cisplatin therapy.

show abstract

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

Abstract: ASCO's update to its antiemetics guideline now includes an evaluation of evidence on complementary antiemetic therapy.

Cited by 200 publications

References 6 publications

A Prospective Multicenter Study Evaluating Secondary Adrenal Suppression After Antiemetic Dexamethasone Therapy in Cancer Patients Receiving Chemotherapy: A Korean South West Oncology Group Study

A Prospective Multicenter Study Evaluating Secondary Adrenal Suppression After Antiemetic Dexamethasone Therapy in Cancer Patients Receiving Chemotherapy: A Korean South West Oncology Group Study

Corticosteroids, the oldest agent in the prevention of chemotherapy-induced nausea and vomiting: What about the guidelines?

Efficacy of Aprepitant for Nausea in Patients with Head and Neck Cancer Receiving Daily Cisplatin Therapy

Contact Info

Product

Resources

About